Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of novel protein kinase inhibitors for cancer therapy.
About me
Mingfeng Yu completed his PhD in organic chemistry at the University of Sydney under the supervision of Professors Matthew H. Todd and Peter J. Rutledge in 2013. His PhD research entailed the design, synthesis and evaluation of novel scorpionand metal-cyclam complexes appended with biologically-active motifs. He was appointed as a Research Fellow (Medicinal Chemistry) at the University of South Australia upon completion of his PhD. Under the guidance of Professor Shudong Wang, he is currently involved in the discovery and development of novel protein kinase inhibitors for cancer therapy.
About me
Research
Excludes commercial-in-confidence projects.
Discovery of CDK6 inhibitors for treatment of childhood medulloblastoma, Channel 7 Children's Research Foundation of SA, 01/01/2015 - 31/12/2016
New treatment for childhood leukaemia, Channel 7 Children's Research Foundation of SA, 01/01/2016 - 31/12/2016
Research
Research since 2008 is shown below. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2021 |
1
|
| 2021 |
|
| 2021 |
2
1
1
|
| 2021 |
|
| 2021 |
1
1
1
|
| 2020 |
1
|
| 2020 |
9
10
4
|
| 2019 |
4
3
|
| 2019 |
Open access
3
3
|
| 2019 |
Open access
12
10
|
| 2018 |
37
40
7
|
| 2018 |
Open access
11
11
|
| 2017 |
Open access
10
10
|
| 2017 |
13
14
2
|
| 2017 |
Open access
17
18
|
| 2017 |
Open access
8
8
2
|
| 2017 |
Open access
35
34
|
| 2016 |
14
14
|
| 2016 |
Open access
16
14
|
| 2016 |
7
7
|
| 2016 |
Open access
29
31
5
|
| 2016 |
Open access
9
9
1
|
| 2016 |
Open access
29
30
2
|
| 2015 |
Open access
|
| 2015 |
24
26
4
|
| 2015 |
Open access
10
11
|
| 2015 |
Open access
19
18
6
|
| 2015 |
25
23
4
|
| 2015 |
27
27
3
|
| 2015 |
Open access
61
61
|
| 2014 |
Open access
67
65
11
|
| 2014 |
Open access
48
48
1
|
| 2014 |
Open access
14
13
3
|
| 2014 |
32
31
6
|
| 2013 |
Open access
11
10
11
|
| 2013 |
Open access
17
15
4
|
| 2011 |
33
33
18
|
| 2010 |
7
7
|
| 2010 |
9
9
|
| 2009 |
|
Research
| Details | Registry | Status |
|---|---|---|
|
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds Wang, Shudong; Zeleke, Solomon Tadesse; Yu, Mingfeng |
WO | Filed |
External engagement & recognition
| Organisation | Country |
|---|---|
| Ain Shams University | EGYPT |
| Cardiff University | UNITED KINGDOM |
| CSIRO Australia (Commonwealth Scientific Industrial Research Organisation) | AUSTRALIA |
| Griffith University | AUSTRALIA |
| Lebanese American University | LEBANON |
| National Research Centre | EGYPT |
| Newcastle University, United Kingdom | UNITED KINGDOM |
| Open University | UNITED KINGDOM |
| Shanghai Jiao Tong University | CHINA |
| University College London | UNITED KINGDOM |
| University of Adelaide | AUSTRALIA |
| University of Nottingham | UNITED KINGDOM |
| University of Oxford | UNITED KINGDOM |
| University of Potsdam | GERMANY |
| University of South Australia | AUSTRALIA |
| University of Southampton | UNITED KINGDOM |
| University of Sydney | AUSTRALIA |
| Westmead Hospital | AUSTRALIA |
| Yabao Pharmaceutical Group Co., Ltd | CHINA |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
Chartered MemberRoyal Australian Chemical Institute (RACI) |
2018 |
MemberAmerican Association for Cancer Research (AACR) |
2018 |
MemberAmerican Association for the Advancement of Science (AAAS) |
2018 |
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| Design and synthesis of mnk Inhibitors for targeted cancer therapy | Current |
| Discovery of cyclin-dependent kinase 2/5 inhibitors for the potential treatment of cancer | Completed |
| Discovery of novel inhibitors of MAPK-interacting kinases as anti-tumour agents | Completed |
| Novel inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents: design, synthesis and evaluation | Completed |
| Protein kinase inhibitors as potential anti-cancer agents: design, synthesis and evaluation | Completed |
